Dr Pascale Tomasini
- Spécialité
- Oncologue médical, expert poumon
- Hôpital
- AP-HM Hôpital Nord (Marseille)
- Derniers articles
-
- The evolving role of Hospital Oncology Pharmacists (HOPs) in assessing therapeutic innovations and managing toxicities in cancer care. (1 janv. 2026)
- Amivantamab Plus Lazertinib in Atypical EGFR-Mutated Advanced Non-Small Cell Lung Cancer: Results From CHRYSALIS-2. (1 janv. 2026)
- Patient-Relevant Outcomes From the Phase III MARIPOSA-2 Trial: Amivantamab-Chemotherapy Versus Chemotherapy in EGFR-Mutant Advanced Non-Small-Cell Lung Cancer Following Disease Progression on Osimertinib. (20 déc. 2025)
- Is adjuvant chemotherapy beneficial in NSCLC patients over 75? Insights from a retrospective analysis. (1 oct. 2025)
- Enhanced Versus Standard Dermatologic Management With Amivantamab-Lazertinib in EGFR-Mutated Advanced NSCLC: The COCOON Global Randomized Controlled Trial. (1 oct. 2025)